Follow The Filings

ACRV Acrivon Therapeutics

Acrivon Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ACRV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ACRV insider trades
  • $114K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Peter Blume-Jensen CEO, +1 joint filer
    Buy
    $82K 49,000 shares at $1.68 +2.4% to stake
    Traded Jan 14 Filed Jan 16
    ↗
  2. Adam D. Levy CFO
    Buy
    $15K 8,832 shares at $1.70 +73% to stake
    Traded Jan 14 Filed Jan 16
    ↗
  3. Eric Devroe COO
    Buy
    $17K 10,000 shares at $1.72 +15% to stake
    Traded Jan 13 Filed Jan 15
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 share withholdings for taxes, 17 stock grants, and 10 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 5 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.